Trial · NCT05142722
Registered outcomes20
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 20
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 84 [PUC] | 84 Days | LS mean percent change from baseline to Day 84 in Low-Density Lipoprotein Cholesterol (LDL-C) in the obicetrapib group compared to the placebo group \[PUC\]. LDL-C level was measured by preparative ultracentrifugation (PUC). |
| Secondary | Percent Change in Low Density Lipoprotein-Cholesterol (LDL-C) From Baseline to Day 180 [Martin/Hopkins] | 180 Days | LS mean percent change from baseline to Day 180 in Low-Density Lipoprotein Cholesterol (LDL-C) in the obicetrapib group compared to the placebo group \[Martin/Hopkins\]. LDL-C value was calculated using the Martin/Hopkins equation unless TG \>= 400 mg/dL or LDL-C \<= 50 mg/dL; where, LDL-C value was measured directly by preparative ultracentrifugation (PUC). |
| Secondary | Percent Change in Low Density Lipoprotein-Cholesterol (LDL-C) From Baseline to Day 365 [PUC] | 365 Days | LS mean percent change from baseline to Day 365 in Low-Density Lipoprotein Cholesterol (LDL-C) in the obicetrapib group compared to the placebo group \[PUC\]. LDL-C level was measured by preparative ultracentrifugation (PUC). |
| Secondary | Percent Change in Apolipoprotein B (ApoB) From Baseline to Day 84 | 84 Days | LS mean percent change from baseline to Day 84 in apolipoprotein B (ApoB) in obicetrapib group compared to the placebo group. |
| Secondary | Percent Change in Apolipoprotein B (ApoB) From Baseline to Day 180 | 180 Days | LS mean percent change from baseline to Day 180 in apolipoprotein B (ApoB) in obicetrapib group compared to the placebo group. |
| Secondary | Percent Change in Apolipoprotein B (ApoB) From Baseline to Day 365 | 365 Days | LS mean percent change from baseline to Day 365 in apolipoprotein B (ApoB) in obicetrapib group compared to the placebo group. |
| Secondary | Percent Change in Non-HDL-C From Baseline to Day 84 | 84 Days | LS mean percent change from baseline to Day 84 in Non-high-density Lipoprotein Cholesterol (Non-HDL-C) in obicetrapib group compared to the placebo group. |
| Secondary | Percent Change in Non-HDL-C From Baseline to Day 180 | 180 Days | LS mean percent change from baseline to Day 180 in Non-high-density Lipoprotein Cholesterol (non-HDL-C) in obicetrapib group compared to the placebo group. |
| Secondary | Percent Change in Non-HDL-C From Baseline to Day 365 | 365 Days | LS mean percent change from baseline to Day 365 in Non-high-density Lipoprotein Cholesterol (non-HDL-C) in obicetrapib group compared to the placebo group. |
| Secondary | Percent Change in HDL-C From Baseline to Day 84 | 84 Days | LS mean percent change from baseline to Day 84 in High-density Lipoprotein Cholesterol (HDL-C) in obicetrapib group compared to the placebo group. |
| Secondary | Percent Change in HDL-C From Baseline to Day 180 | 180 Days | LS mean percent change from baseline to Day 180 in High-density Lipoprotein Cholesterol (HDL-C) in obicetrapib group compared to the placebo group. |
| Secondary | Percent Change in HDL-C From Baseline to Day 365 | 365 Days | LS mean percent change from baseline to Day 365 in High-density Lipoprotein Cholesterol (HDL-C) in obicetrapib group compared to the placebo group. |
| Secondary | Percent Change in Lp(a) From Baseline to Day 84 | 84 Days | LS mean percent change from baseline to Day 84 in Lipoprotein (a) \[Lp(a)\] in obicetrapib group compared to the placebo group. |
| Secondary | Percent Change in Apolipoprotein A1 (ApoA1) From Baseline to Day 84 | 84 Days | LS mean percent change from baseline to Day 84 in Apolipoprotein A1 (ApoA1) in obicetrapib group compared to the placebo group. |
| Secondary | Percent Change in Total Cholesterol From Baseline to Day 84 | 84 Days | LS mean percent change from baseline to Day 84 in Total Cholesterol (TC) in obicetrapib group compared to the placebo group. |
| Secondary | Percent Change in Total Cholesterol From Baseline to Day 180 | 180 Days | LS mean percent change from baseline to Day 180 in Total Cholesterol in obicetrapib group compared to the placebo group. |
| Secondary | Percent Change in Total Cholesterol From Baseline to Day 365 | 365 Days | LS mean percent change from baseline to Day 365 in Total Cholesterol in obicetrapib group compared to the placebo group. |
| Secondary | Percent Change in Triglycerides From Baseline to Day 84 | 84 Days | LS mean percent change from baseline to Day 84 in Triglycerides in obicetrapib group compared to the placebo group. |
| Secondary | Percent Change in Triglycerides From Baseline to Day 180 | 180 Days | LS mean percent change from baseline to Day 180 in Triglycerides in obicetrapib group compared to the placebo group. |
| Secondary | Percent Change in Triglycerides From Baseline to Day 365 | 365 days | LS mean percent change from baseline to Day 365 in Triglycerides in obicetrapib group compared to the placebo group. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05142722/registered